The advent of targeted therapeutics and implications for pathologists.
Hess
Jay L
JL
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D015195:Drug Design; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D010336:Pathology / Q000193:education / Q000639:trends*; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases